299 related articles for article (PubMed ID: 34525346)
1. RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy.
Magdy T; Jiang Z; Jouni M; Fonoudi H; Lyra-Leite D; Jung G; Romero-Tejeda M; Kuo HH; Fetterman KA; Gharib M; Burmeister BT; Zhao M; Sapkota Y; Ross CJ; Carleton BC; Bernstein D; Burridge PW
Cell Stem Cell; 2021 Dec; 28(12):2076-2089.e7. PubMed ID: 34525346
[TBL] [Abstract][Full Text] [Related]
2. Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes.
Christidi E; Huang H; Shafaattalab S; Maillet A; Lin E; Huang K; Laksman Z; Davis MK; Tibbits GF; Brunham LR
Sci Rep; 2020 Jun; 10(1):10363. PubMed ID: 32587261
[TBL] [Abstract][Full Text] [Related]
3. RARG S427L attenuates the DNA repair response to doxorubicin in induced pluripotent stem cell-derived cardiomyocytes.
Huang H; Christidi E; Shafaattalab S; Davis MK; Tibbits GF; Brunham LR
Stem Cell Reports; 2022 Apr; 17(4):756-765. PubMed ID: 35364012
[TBL] [Abstract][Full Text] [Related]
4. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.
Burridge PW; Li YF; Matsa E; Wu H; Ong SG; Sharma A; Holmström A; Chang AC; Coronado MJ; Ebert AD; Knowles JW; Telli ML; Witteles RM; Blau HM; Bernstein D; Altman RB; Wu JC
Nat Med; 2016 May; 22(5):547-56. PubMed ID: 27089514
[TBL] [Abstract][Full Text] [Related]
5. Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity.
Magdy T; Jouni M; Kuo HH; Weddle CJ; Lyra-Leite D; Fonoudi H; Romero-Tejeda M; Gharib M; Javed H; Fajardo G; Ross CJD; Carleton BC; Bernstein D; Burridge PW
Circulation; 2022 Jan; 145(4):279-294. PubMed ID: 34874743
[TBL] [Abstract][Full Text] [Related]
6. All-trans retinoic acid (ATRA) regulates key genes in the RARG-TOP2B pathway and reduces anthracycline-induced cardiotoxicity.
Hasbullah JS; Scott EN; Bhavsar AP; Gunaretnam EP; Miao F; Soliman H; Carleton BC; Ross CJD
PLoS One; 2022; 17(11):e0276541. PubMed ID: 36331922
[TBL] [Abstract][Full Text] [Related]
7. Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes.
Maillet A; Tan K; Chai X; Sadananda SN; Mehta A; Ooi J; Hayden MR; Pouladi MA; Ghosh S; Shim W; Brunham LR
Sci Rep; 2016 May; 6():25333. PubMed ID: 27142468
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes.
Cui N; Wu F; Lu WJ; Bai R; Ke B; Liu T; Li L; Lan F; Cui M
J Cell Mol Med; 2019 Jul; 23(7):4627-4639. PubMed ID: 31106979
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline-Induced Cardiotoxicity: Molecular Insights Obtained from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
Bozza WP; Takeda K; Alterovitz WL; Chou CK; Shen RF; Zhang B
AAPS J; 2021 Mar; 23(2):44. PubMed ID: 33719006
[TBL] [Abstract][Full Text] [Related]
10. Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes.
Fonoudi H; Jouni M; Cejas RB; Magdy T; Blancard M; Ge N; Shah DA; Lyra-Leite DM; Neupane A; Gharib M; Jiang Z; Sapkota Y; Burridge PW
JACC CardioOncol; 2024 Feb; 6(1):38-50. PubMed ID: 38510289
[TBL] [Abstract][Full Text] [Related]
11. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
[TBL] [Abstract][Full Text] [Related]
12. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
[TBL] [Abstract][Full Text] [Related]
13. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
14. The Role of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 Single-nucleotide Polymorphisms in the Doxorubicin-induced Cardiotoxicity in Solid Childhood Tumors.
Gündüz A; Duman D; Başbinar Y; Taşdelen B; Küpeli S; Karpuz D
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e65-e70. PubMed ID: 37828659
[TBL] [Abstract][Full Text] [Related]
15. The Tumor-Suppressive Human Circular RNA CircITCH Sponges miR-330-5p to Ameliorate Doxorubicin-Induced Cardiotoxicity Through Upregulating SIRT6, Survivin, and SERCA2a.
Han D; Wang Y; Wang Y; Dai X; Zhou T; Chen J; Tao B; Zhang J; Cao F
Circ Res; 2020 Jul; 127(4):e108-e125. PubMed ID: 32392088
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional co-activators YAP1-TAZ of Hippo signalling in doxorubicin-induced cardiomyopathy.
Berecz T; Yiu A; Vittay O; Orsolits B; Mioulane M; Dos Remedios CG; Ketteler R; Merkely B; Apáti Á; Harding SE; Hellen N; Foldes G
ESC Heart Fail; 2022 Feb; 9(1):224-235. PubMed ID: 34931757
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomic study of anthracycline-induced cardiotoxicity in Mexican pediatric patients.
Vargas-Neri JL; Carleton B; Ross CJ; Medeiros M; Castañeda-Hernández G; Clark P
Pharmacogenomics; 2022 Apr; 23(5):291-301. PubMed ID: 35147047
[No Abstract] [Full Text] [Related]
18. Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?
Magdy T; Burmeister BT; Burridge PW
Pharmacol Ther; 2016 Dec; 168():113-125. PubMed ID: 27609196
[TBL] [Abstract][Full Text] [Related]
19. Rosmarinic Acid as a Candidate in a Phenotypic Profiling Cardio-/Cytotoxicity Cell Model Induced by Doxorubicin.
Zhang Q; Li J; Peng S; Zhang Y; Qiao Y
Molecules; 2020 Feb; 25(4):. PubMed ID: 32075047
[TBL] [Abstract][Full Text] [Related]
20. Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced Cardiotoxicity.
Siemens A; Rassekh SR; Ross CJD; Carleton BC
Ther Drug Monit; 2023 Jun; 45(3):337-344. PubMed ID: 36728273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]